METHODS: Patients with EDE will be randomly divided into IPL, HEM, VTPS and EMD groups and will be followed up for 6 weeks. The primary outcome measure will be non-invasive tear breakup time (NITBUT). The secondary outcome measures will include, TFLL score, meibomian gland quality and expressibility change from baseline conjunctivocorneal staining with fluorescein and lissamine, tear meniscus height, conjunctival hyperaemia (redness score) and ocular surface disease index questionnaire. Additionally, adverse events will be monitored and documented.
BACKGROUND: Ethics approval number: IRB(2023)K019.01. The findings will be shared regardless of the effect\'s direction.
BACKGROUND: NCT05923528.
方法:将患有EDE的患者随机分为IPL,HEM,VTPS和EMD组并将随访6周。主要结果测量将是非侵入性泪液破裂时间(NITBUT)。次要结果措施将包括,TFLL得分,睑板腺的质量和表达性从基线结膜角膜染色的荧光素和lissamine变化,撕裂半月板高度,结膜充血(红肿评分)和眼表疾病指数问卷。此外,不良事件将被监测和记录.
背景:道德批准号:IRB(2023)K019.01。无论影响方向如何,调查结果都将被分享。
背景:NCT05923528。